What is Genelux Corporation's market cap?

Genelux Corporation (GNLX) has a market capitalization of $123.5M and trades on NASDAQ.

Who are Genelux Corporation's competitors?

Genelux Corporation's key competitors include AbbVie, Merck & Co., Corcept Therapeutics Inc., and others. These companies compete in similar markets and product categories.

Who does Genelux Corporation partner with?

Genelux Corporation's notable partners include Newsoara HYK Biopharmaceuticals Co., Ltd., GOG Foundation.

Where is Genelux Corporation headquartered?

Genelux Corporation is headquartered in United States of America and employs approximately 23 people. It has been publicly traded since 2023.

Genelux Corporation (GNLX) Stock Fundamentals & Financials

Market cap

$123.52M-10.2%

Earnings

Q2 2026 report

August 13, 2026

EPS-$0.21Miss by $0.01

Read the full report

Next report

Nov 4, 2026 (in 2 months)

EPS estimate-$0.20

Competitors

By market cap

AbbVie$464.58B+26.4%

Merck & Co.$377.72B+79.9%

Amgen$238.06B+53.6%

Bristol-Myers Squibb$138.03B+42.4%

Corcept Therapeutics$13.0B+76.3%

Replimune Group$1.5B+247%

Genelux Corporation$123.5M-10.2%

Theriva Biologics$11.2M+177%

By revenue growth

Corcept Therapeutics+16.0%

AbbVie+10.4%

Amgen+9.1%

Merck & Co.+4.6%

Bristol-Myers Squibb+3.1%

By net margin

Amgen22.95%+4.0pp

Bristol-Myers Squibb18.87%+8.4pp

AbbVie9.8%+3.3pp

Corcept Therapeutics6.64%-12.0pp

Merck & Co.4.77%-21.0pp

Profile

Genelux Corporation is a late clinical-stage biopharmaceutical company specializing in the development of next-generation oncolytic viral immunotherapies for aggressive and difficult-to-treat solid tumors. The company's proprietary CHOICE platform leverages a modified vaccinia virus (VACV) to create 'off-the-shelf' personalized therapies designed to selectively kill tumor cells and induce a robust, patient-specific immune response. Their lead candidate is currently being evaluated in late-stage trials for platinum-resistant ovarian cancer and recurrent lung cancers.

Competitive position

A late clinical-stage developer with a proprietary discovery platform and in-house cGMP manufacturing capabilities, currently advancing a Phase 3 registrational trial.

GeographiesUnited States, China, Taiwan, Hong Kong, Macau

Customer segmentsPharmaceutical companies, Oncology patients

Business modelR&D intensive, Licensing and royalties, Internal manufacturing

SuppliersRaw material suppliers, Contract laboratories, Clinical research organizations

CustomersStrategic licensing partners, Specialty pharmacies, Hospitals and oncology clinics

CountryUnited States of America

Listed2023

Employees23.0

CEOThomas D. Zindrick

SectorHealthcare

IndustryBiotechnology

Websitegenelux.com

FilingsSEC EDGAR

FAQ

What is Genelux Corporation's market cap?: Genelux Corporation (GNLX) has a market capitalization of $123.5M and trades on NASDAQ.
Who are Genelux Corporation's competitors?: Genelux Corporation's key competitors include AbbVie, Merck & Co., Corcept Therapeutics Inc., and others. These companies compete in similar markets and product categories.
Who does Genelux Corporation partner with?: Genelux Corporation's notable partners include Newsoara HYK Biopharmaceuticals Co., Ltd., GOG Foundation.
Where is Genelux Corporation headquartered?: Genelux Corporation is headquartered in United States of America and employs approximately 23 people. It has been publicly traded since 2023.